Does Belvedere publish lists of the best healthcare stocks?
No. Healthcare pages are disclosure-size universes and methodology-defined screens, not buy lists.
Industry intelligence
Healthcare
Public companies in Belvedere's healthcare universe, with source-linked financials. Valuation multiples are shown only when licensed market data exists.
How are healthcare issuers grouped?
Sector comes from SIC metadata. Sub-filters on data pages (devices, services, biotechnology, and related) are keyword mappings from SIC descriptions and can be imperfect.
Healthcare issuers in this universe are mapped from SIC codes covering devices, services, distribution, and related products. Biotechnology is listed as its own sector when SIC 283x applies. Pages are disclosure-size and filing universes: they report what is tagged in EDGAR. They are not clinical-pipeline rankings, FDA-approval calendars, or lists of stocks to buy.
Companies5
Published research0
GeographyUnited States SEC registrants in this extract
Companies
| Company | Ticker | Industry | Revenue | Growth | Belvedere FCF | Latest filing | Research |
|---|---|---|---|---|---|---|---|
| ANGIODYNAMICS INCNasdaq: ANGO | ANGO | Surgical & Medical Instruments & Apparatus | $78.4M | +8.9% | — | 4 · Jul 31, 2026 | Universe |
| AtriCure, Inc.Nasdaq: ATRC | ATRC | Surgical & Medical Instruments & Apparatus | $153.6M | +12.8% | — | 10-Q · Jul 27, 2026 | Universe |
| CERUS CORPNasdaq: CERS | CERS | Surgical & Medical Instruments & Apparatus | $57.4M | +9.5% | — | 10-Q · Jul 30, 2026 | Universe |
| National Vision Holdings, Inc.Nasdaq: EYE | EYE | Ophthalmic Goods | $498.8M | +2.5% | — | 10-Q · Aug 13, 2026 | Universe |
| ROGERS CORPNYSE: ROG | ROG | Plastic Materials, Synth Resins & Nonvulcan Elastomers | $200.5M | +5.2% | $1.1M | 10-Q · Jul 29, 2026 | Universe |
Research
No Belvedere reports are currently published in this sector.
Research Radar (subset)
- National Vision Holdings, Inc. (EYE) — Revenue: +2.5% · Revenue increased +2.5% ($486.4M to $498.8M; Q2 2025 vs Q3 2026).
- National Vision Holdings, Inc. (EYE) — Revenue acceleration: -4.0 pp · Quarterly revenue YoY growth moved from +6.6% to +2.5% (-4.0 percentage points).
- National Vision Holdings, Inc. (EYE) — Cash: $36.0M · Cash and cash equivalents were $36.0M as of the latest reported balance-sheet date.
- National Vision Holdings, Inc. (EYE) — Share count: $79.1M · Shares outstanding were 79,058,038 as of the latest reported date.
- CERUS CORP (CERS) — Revenue: +9.5% · Revenue increased +9.5% ($52.4M to $57.4M; Q2 2025 vs Q2 2026).
- CERUS CORP (CERS) — Revenue acceleration: -14.6 pp · Quarterly revenue YoY growth moved from +24.1% to +9.5% (-14.6 percentage points).
- CERUS CORP (CERS) — Cash: $18.0M · Cash and cash equivalents were $18.0M as of the latest reported balance-sheet date.
- AtriCure, Inc. (ATRC) — Revenue: +12.8% · Revenue increased +12.8% ($136.1M to $153.6M; Q2 2025 vs Q2 2026).
Related rankings
- Highest Free Cash Flow Margins
- Strongest Balance Sheets
- Companies With Revenue Growth and Positive Free Cash Flow
- Technology Companies by Revenue Growth
- Healthcare Companies by Revenue Growth
- Industrial Companies by Revenue Growth
Frequently asked questions
- Does Belvedere publish lists of the best healthcare stocks?
- No. Healthcare pages are disclosure-size universes and methodology-defined screens, not buy lists.
- How are healthcare issuers grouped?
- Sector comes from SIC metadata. Sub-filters on data pages (devices, services, biotechnology, and related) are keyword mappings from SIC descriptions and can be imperfect.
- Does Belvedere model clinical pipelines?
- Pipeline assets, trial phases, and approval odds are not invented. They appear only in a human-reviewed note that cites a source.